-
Siltartoxatug Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Siltartoxatug Injection (trade name: 新替妥/Xintituo) of Zhuhai Trinomab Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA. This product is indicated for emergency prophylaxis of tetanus in adults.
-
Innovative TCM Compound Binafuxi Granules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Compound Binafuxi Granules of Xinjiang Yinduolan Uighur Medicine Co., Ltd. is approved for marketing by China NMPA.
-
Announcement of the National Medical Products Administration and National Health Commission on Issuing the 2025 Edition of the Pharmacopoeia of the People’s Republic of China (No. 29, 2025)
2025-06-11
According to the Drug Administration Law of the People's Republic of China, the Pharmacopoeia of the People's Republic of China (2025 Edition) (hereinafter referred to as Chinese Pharmacopoeia) has been reviewed and approved by the Plenary Meeting of the Executive Committee of the 12th Chinese Pharmacopoeia Commission.
-
NMPA Announcement on Matters Related to the Implementation of the 2025 Edition of the Pharmacopoeia of the People's Republic of China (No. 32, 2025)
2025-06-11
The 2025 Edition of the Pharmacopoeia of the People's Republic of China (hereinafter referred to as the Chinese Pharmacopoeia) has been issued by Announcement No. 29, 2025 of the National Medical Products Administration and the National Health Commission and shall come into force as of October 01, 2025.
-
Transcatheter Mitral Valve Clip System Approved for Marketing
2025-06-11
Recently, the innovative product Transcatheter Mitral Valve Clip System of Hangzhou Dawneo Medical Technology Co., Ltd. is approved by China NMPA.
-
Aortic Covered Stent System Approved for Marketing
2025-06-11
Recently, the innovative product "Aortic Covered Stent System" of Lifetech Scientific (Shenzhen) Co., Ltd. is approved by China NMPA.
